Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TRIM22

TRIM22

Basics

Aliases:
This biomarker is also known as:
  • tripartite motif-containing 22,
  • STAF50,
  • GPSTAF50,
  • tripartite motif protein TRIM22,
  • Staf-50,
  • 50 kDa-stimulated trans-acting factor,
  • RNF94,
  • tripartite motif-containing protein 22,
  • staf-50,
  • stimulated trans-acting factor (50 kDa),
  • E3 ubiquitin-protein ligase TRIM22,
  • Tripartite motif-containing protein 22,
  • tripartite binding motif 22,
  • tripartite motif containing 22,
  • RING finger protein 94,
  • EC 6.3.2.-,

View in BioMuta

Description…

tripartite motif containing 22

Attributes

QA State: Curated
Type: Gene
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Prostate

Attributes

Phase: One
QA State: Curated

Overview

No additional prostate data available.

Performance Comment

Significance Analysis of Microarray (SAM) was used to develop a 7-gene classifier. The overall prediction accuracy and sensitivity is 71% and 76%, respectively. The inclusion of the Gleason sum to the seven-gene classifier raised the prediction accuracy and sensitivity to 83% and 76% respectively This prognostic signature is closely associated with biochemical recurrence in patients after radical prostatectomy. The seven genes are: RRAGD, PQBP1, HIST1H2BC, ALDH1A2, TRIM22, RBPMS, HSPB8.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

News

The final report of the 2013 Cancer Biomarkers Bioinformatics Workshop is now available.

Announcement 06/26/2014


Please click here to register for the 9th EDRN Scientific Workshop from September 8-10, 2014, in Bethesda, Maryland. The meeting registration page also has agendas and hotel reservation information.
Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html